- Record: found
- Abstract: not found
- Article: not found
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
Masatoshi Kudo ,
Richard S Finn ,
Shukui Qin ,
Kwang-Hyub Han ,
Kenji Ikeda ,
Fabio Piscaglia ,
Ari Baron ,
Joong-Won Park ,
Guohong Han ,
Jacek Jassem ,
Jean Frederic Blanc ,
Arndt Vogel ,
Dmitry Komov ,
T R Jeffry Evans ,
Carlos Lopez ,
Corina Dutcus ,
Matthew Guo ,
Kenichi Saito ,
Silvija Kraljevic ,
Toshiyuki Tamai ,
Min Ren ,
Ann-Lii Cheng
March 2018
March 2018
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
<p class="first" id="d15649127e365">In a phase 2 trial, lenvatinib, an inhibitor of
VEGF receptors 1-3, FGF receptors
1-4, PDGF receptor α, RET, and KIT, showed activity in hepatocellular carcinoma. We
aimed to compare overall survival in patients treated with lenvatinib versus sorafenib
as a first-line treatment for unresectable hepatocellular carcinoma.
</p>